Key Driver Shaping the Future Sotrovimab Or Xevudy Market From 2025-2034: Impact Of Rising COVID-19 Cases On Market Growth

What Is the Forecasted Market Size and Growth Rate for the Sotrovimab Or Xevudy Market?
Recently, the sotrovimab or xevudy market has exhibited a CAGR of $XX. Projections indicate an expansion from $XX million in 2024 to $XX million in 2025, translating to a Compound Annual Growth Rate (CAGR) of $XX%. This growth within the historic period is largely stimulated by factors such as the surge in COVID-19 cases, growing demand for efficient monoclonal antibody treatments, heightened consciousness regarding the care of high-risk patients, increased government funding, and a rise in partnerships among pharmaceutical enterprises.

In the next few years, the market size of sotrovimab, also known as xevudy, is anticipated to grow at $XX% compound annual growth rate (CAGR) and is expected to reach $XX million by 2029. The predicted progress during the forecast period can be credited to the continuous emergence of new variants of COVID-19, the increasing emphasis on monoclonal antibody treatments, extending healthcare reach in underdeveloped areas, escalating government backing for readiness against pandemics, and the growing provision of telehealth services for treatment administration. The forecast period is also likely to witness significant trends including advancements in the production technology of vaccines, innovation in drug formulations, the inclusion of telehealth, advancements in technology for producing antibodies, and progression in antibody engineering technology.

What Factors Are Propelling the Expansion of the Sotrovimab Or Xevudy Market?
The escalation of COVID-19 cases is projected to fuel the expansion of the sotrovimab or xevudy market in the future. COVID-19, caused by the SARS-CoV-2 virus, is transmitted via respiratory droplets and produces effects ranging from a minor fever to serious respiratory conditions. Its proliferation can be mitigated by vaccines and proper hygiene habits. The surge in COVID-19 cases can be attributed to factors like new strains of the virus, waning immunity, relaxed restrictions, indoor gatherings during festive seasons, and irregular vaccine distribution. Sotrovimab can effectively treat COVID-19 high-risk patients by neutralizing the virus early on, thereby averting severe consequences including hospitalization and death. To illustrate, a report from the Office for National Statistics, a UK government department for official statistics, disclosed in March 2023 that approximately 1.9 million people in the UK, or 2.9% of the population, had reported having COVID. Around 92% of these had contracted COVID-19 over 12 weeks prior, 69% had been experiencing symptoms for more than a year and 41% for over two years. Therefore, the surging prevalence of COVID cases is set to propel the growth of the sotrovimab or xevudy market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp

Which Businesses Are at the Forefront of Sotrovimab Or Xevudy Market Development?
Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.

What Are the Latest Innovations in the Sotrovimab Or Xevudy Market?
A dominant trend in the sotrovimab or xevudy market focuses on strategic investments that enhance research and development, scale up production capabilities, and broaden drug accessibility. Such collaborations are essential to quicken distribution and provide wider reach, particularly in regions with high demand. Notably, in January 2022, GSK plc, a leading pharmaceutical firm based in the UK, entered into collaboration with Vir Biotechnology Inc., a biotech firm in the US to announce a crucial contract with the US government to acquire additional sotrovimab resources, a monoclonal antibody approved for early COVID-19 treatment. This contract underscores the continued demand for effective therapeutics as the pandemic situation keeps changing. Sotrovimab is specially crafted for adults and youngsters at high risk of developing severe COVID-19, providing a necessary solution for those not in need of oxygen supplementation. This recent pact signifies GSK and Vir's expansive strategy to keep sotrovimab within reach despite the rise of new virus variants.

How Is the Sotrovimab Or Xevudy Market Segmented?
The sotrovimab or xevudy market covered in this report is segmented -

1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report

Where Is the Sotrovimab Or Xevudy Market Growth Most Prominent?
North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Sotrovimab Or Xevudy Global Market Report?

- Market Size Analysis: Analyze the sotrovimab or xevudy Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the sotrovimab or xevudy Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall sotrovimab or xevudy market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the sotrovimab or xevudy market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.